LYELL IMMUNOPHARMA INC
COM · CUSIP 55083R104
Q1 2025 share counts are adjusted for a 1-for-20 stock split, so holders aren't shown as buying or selling because of it.
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $8.84.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 93 |
| Q4 2022 | 96 |
| Q1 2023 | 100 |
| Q2 2023 | 100 |
| Q3 2023 | 107 |
| Q4 2023 | 120 |
| Q1 2024 | 128 |
| Q2 2024 | 121 |
| Q3 2024 | 118 |
| Q4 2024 | 106 |
| Q1 2025 | 113 |
| Q2 2025 | 6 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2023 | 63 | 31 |
| Q4 2023 | 56 | 43 |
| Q1 2024 | 59 | 58 |
| Q2 2024 | 48 | 66 |
| Q3 2024 | 47 | 53 |
| Q4 2024 | 54 | 57 |
| Q1 2025 | 38 | 42 |
| Q2 2025 | 1 | 112 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2024 | $39.1k | $276 | 0.01 |
| Q4 2024 | $10.8k | $9.8k | 0.90 |
| Q1 2025 | $1.6k | $3.2k | 2.07 |
| Q2 2025 | $0 | $0 | — |
Biggest buyers
| IFP Advisors, Inc | New | +63 |
Biggest sellers
| Foresite Capital Management IV, LLC | Sold out | -800.4k |
| BlackRock, Inc. | Sold out | -636.1k |
| VANGUARD GROUP INC | Sold out | -486.9k |
| Foresite Capital Management V, LLC | Sold out | -406.7k |
| venBio Partners LLC | Sold out | -355.1k |
| PRICE T ROWE ASSOCIATES INC /MD/ | Sold out | -323.9k |
| Alphabet Inc. | Sold out | -293.3k |
| CITADEL ADVISORS LLC | Sold out | -225.3k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -220.0k |
| STATE STREET CORP | Sold out | -185.1k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| ARCH Venture Fund IX, L.P. 13G · exempt (held before listing) filed 2025-02-14 | 13.1% |
| Foresite Capital Fund IV, L.P. 13G · passive investor +2.5 pts · filed 2025-05-15 | 9.2% |
| Explore Investments LLC/DE 13G · passive investor new · filed 2025-08-19 | 5.4% |
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| MWG Management Ltd. 17.17% of their portfolio | 1.0m $8.9m | Reduced -1 |
| Orland Properties Ltd 2.83% of their portfolio | 754.7k $6.7m | Reduced -0 |
| Decheng Capital LLC 1.33% of their portfolio | 595.5k $5.3m | Reduced -1 |
| JOHNSON & JOHNSON 0.11% of their portfolio | 41.2k $368.0k | Reduced -1 |
| TAKEDA PHARMACEUTICAL CO LTD 1.86% of their portfolio | 41.2k $363.9k | Reduced -1 |
| IFP Advisors, Inc 0.00% of their portfolio | 63 $28 | New |